# ARTEMIS-011 (NCT06935409)

> Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06935409
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hansoh BioMedical R&D Company
- Conditions: Osteosarcoma
- Interventions: HS-20093; Gemcitabine combined with docetaxel
- Enrollment: 122
- Primary outcome: PFS assessed by IRC as per RECIST 1.1 criteria

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 21
- YouTube: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=artemis-011-nct06935409

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06935409", "email": "<work email>"}; the inbox owner confirms by the emailed link.